Fassihi SC, et al. - A systematic was conducted to evaluate the existing literature on the outcomes, complications, and survivorship of primary total hip arthroplasty (THA) in sickle cell disease (SCD) individuals. Researchers performed a systematic search applying Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines of PubMed, MEDLINE, EMBASE, and Cochrane databases for clinical studies on THA in SCD individuals. This research enrolled studies on primary THA in SCD individuals with a mean follow-up greater than 90 days. This analysis included 16 studies including a total of 5,193 SCD individuals. For osteonecrosis of the hip, it was demonstrated that THA remains an effective treatment modality in SCD individuals. Nevertheless, these individuals are at elevated risk of medical and surgical complications. In this patient population, surgeons should be aware of the unique challenges when counseling and managing these individuals in the perioperative period.